SHARE

A company you may not have heard of – but one that really deserves some close attention right now for growth-oriented small and micro-cap investors – is Innovest Global Inc (OTCMKTS:IVST). This is a conglomerate player with multiple lines of business. And that spread of diversified sales growth potential is expanding right now with the company’s recent announcement that it is in late-stage negotiations with a revenue-positive addition in Construction.

IVST shares have been holding strong at key support, up about 10% in the past week, and trading above both the 50-day and 200-day simple moving averages. The stock is trading along a shelf of support that represents the corrective floor of a consolidation underway since March of this year. That consolidation comes in the context of a larger time frame bull market that has granted as much as 4,800% in gains since late 2017. But, as noted, we have seen a six-month consolidation already play out, suggesting this stock could be ready to get started on a potential new leg of the bull trend.

Innovest Global Inc (OTCMKTS:IVST) casts itself as a diversified holding company, focuses on identifying and acquisition of qualified mineral prospects.

This is a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Innovest Global utilizes novel technology and marketing to efficiently acquire customers.

The company’s primary growth strategy is to acquire existing companies in a select few industries and attract new customers in cost-effective ways. Currently, it has a Commercial & Industrial Division, and a Biotechnology & Health Services Division.

The company recently took a strong stake in StemVax Therapeutics, a Translational Biotechnology Company that develops novel therapies for brain tumor patients. The company focuses its efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer.

The company also focuses its research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells. It seeks to “make a difference in patient’s lives. Bringing new beginnings to the market by developing novel therapeutics. Dr. Dwain Morris-Irvin, President of Innovest’s Biotech division is the StemVax founder and Chief Science Officer.”

Cedars-Sinai Medical Center is a non-profit hospital and academic health science center located in Los Angeles, California. They employ over 2,000 physicians and are considered one of the top hospitals and research organizations in the world. Dr. Irvin previously was one of their key contributors in the areas of research that he founded StemVax to pursue.

The company was formerly known as Aurum Resource and Asset Management, Inc. and changed its name to Innovest Global, Inc. in January 2017. Innovest Global, Inc. was incorporated in 1999 and is based in Las Vegas, Nevada.

Clicking on All Cylinders

As noted above, IVST is a diversified conglomerate looking to add a construction segment to its broad strategic portfolio. The company’s biotech segment has also recently been making some waves, including a possible patent approval in the works.

“With the recently announced patent approval, and obtaining exclusive worldwide rights to the technology, we believe that now is the time to collaborate with other scientists that have technologies which serve Innovest’s mission and could benefit from the relationship,” said Dr. Dwain Morris-Irvin, Biotech Division President and the StemVax founder.

At this time, carrying a capital value in the market of $29.48M, IVST has a strong balance sheet, with a store ($561K) of cash on the books balanced by about $366K in total current liabilities.

IVST is pulling in trailing 12-month revenues of $1.9M. In addition, the company is seeing recent top-line growth, with sequential quarterly revenues growing at 55.8%.

As more color becomes clear on the name, we will review the situation and update our take.

LEAVE A REPLY